Literature DB >> 24770569

Long-term (4 years) results of choroidal hemangioma treated with proton beam irradiation.

A Zeisberg1, I Seibel, D Cordini, N Lakotka, G Willerding, L Moser, J Heufelder, A M Joussen.   

Abstract

BACKGROUND: The aim of this retrospective study was to determine the efficacy of proton beam irradiation in choroidal hemangioma in a long-term follow-up. PATIENTS AND METHODS: A total dose of 20 Cobalt Gray equivalent (CGE) was administered to 50 eyes of 50 patients from September 1998 to September 2010. All treated patients presented with a symptomatic tumor. Nine patients were pre-treated by photodynamic therapy (PDT). Visual outcome, tumor regression, and complications resulting from radiation were investigated.
RESULTS: The mean follow-up was 55.4 months (range 13-132). Tumor thickness decreased in all patients. Retinal re-attachment was achieved without evidence of tumor leakage. Visual acuity improved by two lines after one year in 43.4 % of patients and after two years in 36.8 % of patients. During the 55.4 months of long-term follow-up the visual acuity improved from 6/15 to 6/12 after proton therapy. Twenty-three patients (46.0 %) developed radiation retinopathy. According to the Finger classification of 2004, 21 patients (42.0 %) showed a stage 1 or 2 (functionally not relevant) retinopathy, and two patients (4.0 %) presented a stage 3 or 4 (functionally relevant) retinopathy. Further complications included sicca syndrome in nine cases, cataract formation in 10 cases, and radiation optic neuropathy in four cases.
CONCLUSION: Proton therapy with 20 CGE is an efficient primary therapy in choroidal hemangioma and is very effective as a secondary treatment after PDT.

Entities:  

Mesh:

Year:  2014        PMID: 24770569     DOI: 10.1007/s00417-014-2635-1

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  19 in total

Review 1.  The role of photodynamic therapy in the treatment of symptomatic choroidal hemangioma.

Authors:  Bernhard Jurklies; Norbert Bornfeld
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-02-08       Impact factor: 3.117

2.  Photodynamic therapy using verteporfin in circumscribed choroidal haemangioma.

Authors:  B Jurklies; G Anastassiou; S Ortmans; A Schüler; H Schilling; U Schmidt-Erfurth; N Bornfeld
Journal:  Br J Ophthalmol       Date:  2003-01       Impact factor: 4.638

3.  Photodynamic therapy of subfoveal choroidal neovascularization: clinical and angiographic examples.

Authors:  U Schmidt-Erfurth; J Miller; M Sickenberg; A Bunse; H Laqua; E Gragoudas; L Zografos; R Birngruber; H van den Bergh; A Strong; U Manjuris; M Fsadni; A M Lane; B Piguet; N M Bressler
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1998-05       Impact factor: 3.117

4.  Long-term results after low dose ocular irradiation for choroidal haemangiomas.

Authors:  H Schilling; W Sauerwein; A Lommatzsch; W Friedrichs; S Brylak; N Bornfeld; A Wessing
Journal:  Br J Ophthalmol       Date:  1997-04       Impact factor: 4.638

5.  Circumscribed choroidal hemangiomas.

Authors:  R Anand; J J Augsburger; J A Shields
Journal:  Arch Ophthalmol       Date:  1989-09

6.  Circumscribed choroidal hemangioma: clinical manifestations and factors predictive of visual outcome in 200 consecutive cases.

Authors:  C L Shields; S G Honavar; J A Shields; J Cater; H Demirci
Journal:  Ophthalmology       Date:  2001-12       Impact factor: 12.079

7.  Choroidal hemangioma treated with photodynamic therapy using verteporfin.

Authors:  S A Madreperla
Journal:  Arch Ophthalmol       Date:  2001-11

8.  Proton beam irradiation of choroidal hemangiomas.

Authors:  L Zografos; E Egger; L Bercher; L Chamot; G Munkel
Journal:  Am J Ophthalmol       Date:  1998-08       Impact factor: 5.258

9.  Long-term results of low-dose proton beam therapy for circumscribed choroidal hemangiomas.

Authors:  Christine Levy-Gabriel; Livia Lumbroso-Le Rouic; Corinne Plancher; Remi Dendale; Sabine Delacroix; Bernard Asselain; Jean-Louis Habrand; Laurence Desjardins
Journal:  Retina       Date:  2009-02       Impact factor: 4.256

10.  Longstanding symptomatic choroidal hemangioma managed with limited PDT as initial or salvage therapy.

Authors:  F D Verbraak; R O Schlingemann; J E E Keunen; M D de Smet
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-10-18       Impact factor: 3.117

View more
  7 in total

1.  Results of external beam radiotherapy for diffuse choroidal hemangiomas in Sturge-Weber syndrome.

Authors:  Matthieu Randon; Christine Lévy-Gabriel; Rachid Abbas; Rémi Dendale; Livia Lumbroso; Laurence Desjardins; Nathalie Cassoux
Journal:  Eye (Lond)       Date:  2018-02-06       Impact factor: 3.775

2.  Retinal cavernous haemangioma treated by proton beam therapy.

Authors:  Amir Mahdjoubi; Rémi Dendale; Livia Lumbroso-Le Rouic; Laurence Desjardins; Nathalie Cassoux
Journal:  Int Ophthalmol       Date:  2017-02-21       Impact factor: 2.031

Review 3.  Circumscribed choroidal hemangioma: A case report and literature review.

Authors:  Morgan Berry; Linda J H Lucas
Journal:  J Optom       Date:  2016-02-10

4.  Clinical outcomes and predictors of response to photodynamic therapy in symptomatic circumscribed choroidal hemangioma: A retrospective case series.

Authors:  Yeen-Fey Ho; Anne Chao; Kuan-Jen Chen; An-Ning Chao; Nan-Kai Wang; Laura Liu; Yen-Po Chen; Yih-Shiou Hwang; Wei-Chi Wu; Chi-Chun Lai; Tun-Lu Chen
Journal:  PLoS One       Date:  2018-05-31       Impact factor: 3.240

5.  Radiation therapy for exudative choroidal hemangioma.

Authors:  Paul T Finger
Journal:  Indian J Ophthalmol       Date:  2019-05       Impact factor: 1.848

6.  Application of ICG-enhanced thermocoagulation method and photodynamic therapy in circumscribed choroidal hemangioma.

Authors:  Chuan Tian; Xi Chen; Jin Cao; Lu Yang
Journal:  Oncol Lett       Date:  2018-02-15       Impact factor: 2.967

Review 7.  Circumscribed choroidal hemangioma: An overview of clinical manifestation, diagnosis and management.

Authors:  Mrittika Sen; Santosh G Honavar
Journal:  Indian J Ophthalmol       Date:  2019-12       Impact factor: 1.848

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.